Wilex  
WILEX AG是一家生物制药公司，总部在德国慕尼黑。公司专注于肿瘤学，开发用于各类癌症的针对性检测和靶向治疗的、基于抗体和小分子的诊断和治疗候选产品。WILEX Inc.除了生产、营销生物标记检测试剂以外，其子公司Heidelberg Pharma GmbH还提供临床前合同研究服务和一种抗体药物螯合物(ADC)技术平台。其商业模式包含研究和产品开发以及这些活动的商业化。我们的客户和合作伙伴包括领先的国际性制药公司。WILEX AG在法兰克福证券交易所挂牌上市。ISIN DE0006614720 / WKN 661472 /代码WL6。
 

WILEX Inc.是德国WILEX AG的全资美国子公司，采用Oncogene Science这一品牌名称生产、推广和销售基于血清的肿瘤蛋白诊断试剂和各类生物标记检测试剂。其产品阵容包括酶联免疫吸附检测(ELISA)和免疫组织化学(IHC)检测。为了达到为世界各地癌症患者的治疗方案提供支持的目的，WILEX Inc.提供用于测量肿瘤基因、生长因子受体(HER-2/neu, EGFr)、蛋白酶和蛋白酶抑制剂(uPA, PAI-1, TIMP-1)以及缺氧标记(CA IX)的生物标记检测试剂。新款CA IX IHC是一种1类IVD检测，除此以外，WILEX Inc.还提供唯一获得FDA批准的测量血清HER-2/neu水平的IVD ELISA，HER-2/neu用于转移性乳腺癌女性患者的处治和监测。WILEX Inc.总部位于美国马萨诸塞州剑桥市，同时提供GMP和ISO认证的生产服务。

WILEX AG is a biopharmaceutical company based in Munich, Germany. Focused on oncology, the Company develops diagnostic and therapeutic product candidates for the specific detection and targeted treatment of various types of cancer based on antibodies and small molecules. Beside the manufacturing and marketing of the biomarker tests from WILEX Inc. the subsidiary Heidelberg Pharma GmbH offers preclinical contract research services and an antibody drug conjugate (ADC) technology platform. The business model comprises research and product development as well as the commercialisation of its activities. Our customers and partners include leading international pharmaceutical companies. WILEX AG is listed at the Frankfurt Stock Exchange. ISIN DE0006614720 / WKN 661472 / Symbol WL6.
t WILEX Inc.
WILEX Inc. is a wholly owned US subsidiary of WILEX AG, Munich, Germany and manufactures, markets and sells serum based oncoprotein diagnostics and various biomarker tests under the brand name Oncogene Science. The product portfolio includes Enzyme-linked ImmunoSorbent Assays (ELISA) and immunohistochemical (IHC) assays. With the aim of supporting treatment regimens for cancer patients worldwide WILEX Inc. offers biomarker tests for measuring oncogenes, growth factor receptors (HER-2/neu, EGFr), proteases and protease inhibitors (uPA, PAI-1, TIMP-1), as well as markers of hypoxia (CA IX). In addition to the new CA IX IHC which is a class 1 IVD test, WILEX Inc. provides the only FDA-cleared IVD ELISA that measures the serum HER-2/neu level for the management and monitoring of patient care for women with metastatic breast cancer. WILEX Inc. is based in Cambridge, MA, USA and also provides GMP and ISO certified manufacturing services. More information is available on .